Correlation between Serum TGF-β1,TSP1,SCCA Levels and Radiothera-peutic Effect in Patients with Advanced Esophageal Cancer before Radio-therapy

YI Chengfeng; CHEN Xiaoying; HU Xiangchen; PENG Rong; XIE Fapeng

doi:10.3969/j.issn.1002-3429.2024.20.010

Abstract：Objective To analyze the correlation between the levels of serum transforming growth factor-β1(TGF-β1),thrombospondin-1(TSP1),squamous cell carcinoma antigen(SCCA)and radiotherapeutic effect in patients with advanced esophageal cancer before radiotherapy,so as to facilitate the formulation of clinical treatment plans and prevent de-layed treatment.Methods The clinical data of 109 patients with advanced esophageal cancer treated with radiotherapy from June 2019 to June 2023 were retrospectively analyzed and divided into an ineffective group(n=21)and an effective group(n=88)according to the radiotherapeutic effect.The clinical data of the two groups were compared,and the factors influen-cing the radiotherapeutic effect of patients with advanced esophageal cancer were analyzed by binary Logistic regression model.The predictive value of TGF-β1,TSP1 and SCCA before radiotherapy was analyzed by drawing receiver operating characteristic(ROC)curve.Results The proportion of patients with clinical stageⅣand radiotherapy dose≤60 Gy in the ineffective group was higher than that in the effective group(P＜0.05).The serum levels of TGF-β1 and SCCA in the two groups after radiother-apy were lower than those before radiotherapy,while the levels of TSP1 were higher than those before radiotherapy(P＜0.05).Serum TGF-β1 and SCCA levels in the effective group were lower than those in the ineffective group before and after radiothera-py,while TSP1 levels were higher than those in the ineffective group(P＜0.05,P＜0.01).Binary Logistic regression analysis showed that clinical stage and serum TGF-β1,TSP1 and SCCA levels before radiotherapy were all risk factors for radiotherapeu-tic effect in patients with advanced esophageal cancer(P＜0.01).ROC curve analysis showed that serum TGF-β1,TSP1 and SCCA levels alone and in combination before radiotherapy were effective in predicting the radiotherapeutic effect of patients with advanced esophageal cancer.At 12-month follow-up,the survival rate of the effective group was 89.77%(79/88),which was higher than that of the ineffective group[66.67%(14/21)],showing significant differences(P＜0.01).Conclusion There is a close relationship of radiotherapeutic effect with clinical stage and serum levels of TGF-β1,TSP1 and SCCA in patients with advanced esophageal cancer before radiotherapy.In clinical practice,it is possible to predict radiotherapeutic effect of patients with advanced esophageal cancer by detecting serum levels of TGF-β1,TSP1 and SCCA before radiotherapy,which can help guide the formulation of clinical treatment plans,prevent delayed treatment,and improve survival rates of patients.